Phase 2 Study of NGM282 in Patients With Primary Biliary Cirrhosis

A Phase 2, Randomized, Double Blind, Placebo Controlled, Parallel Group, Multiple Center Study to Evaluate the Safety, Tolerability, and Pharmacodynamic Activity of NGM282 in Combination With Ursodeoxycholic Acid (UDCA) Administered for 28 Days in Patients With Primary Biliary Cirrhosis

The purpose of this study is to determine the safety, tolerability, and activity of NGM282 in patients with Primary Biliary Cirrhosis.

Inclusion Criteria:

• Males or females, between 18 and 75 years of age, inclusive
• PBC diagnosis consistent with AASLD and EASL guidelines
• Stable dose of UDCA

Exclusion Criteria:

• Chronic liver disease of a non-PBC etiology
• Evidence of clinically significant hepatic decompensation